2246607-08-7
2246607-08-7
Chemical Structure
Inupadenant
Synonym(s): EOS-850
- CAS No.: 2246607-08-7
- Formula:C25H26F2N8O4S2
- Molecular Weight:604.65
IUPAC Name: (S)-5-amino-3-(2-(4-(2,4-difluoro-5-(2-(methylsulfinyl)ethoxy)phenyl)piperazin-1-yl)ethyl)-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidin-2(3H)-one
InChIKey: QYCCLUSYHJXDEX-RWYGWLOXSA-N
SMILES: O=C1SC(C2=NC(C3=CC=CO3)=NN2C(N)=N4)=C4N1CCN5CCN(C(C(F)=C6)=CC(OCC[S@](C)=O)=C6F)CC5
Biological Activity: Inupadenant is an orally active, highly selective A2A receptor antagonist. Inupadenant can not cross BBB. Inupadenant can enhance the humoral immune response and has anti-tumor activity[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Inupadenant | 98.27% | Inupadenant is an orally active, highly selective A2A receptor antagonist. Inupadenant can not cross BBB. Inupadenant can enhance the humoral immune response and has anti-tumor activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Laurence Buisseret, et al. Phase 1 trial of the adenosine A2Areceptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor. Journal of Clinical Oncology. Volume 39, Issue 15_suppl.
- [2]. Tieppo P, et al. 48P The A2AR antagonist inupadenant promotes humoral responses in preclinical models. Immuno-Oncology and Technology, 2024, 24.
